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Genome editing technology, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases
(TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas, has enabled far more efficient
genetic engineering even in non-human primates. This biotechnology is more likely to develop into medicine for
preventing a genetic disease if corrective genome editing is integrated into assisted reproductive technology,
represented by in vitro fertilization. Although rapid advances in genome editing are expected to make germline
gene correction feasible in a clinical setting, there are many issues that still need to be addressed before this could
occur. We herein examine current status of genome editing in mammalian embryonic stem cells and zygotes and
discuss potential issues in the international regulatory landscape regarding human germline gene modification.
Moreover, we address some ethical and social issues that would be raised when each country considers whether
genome editing-mediated germline gene correction for preventive medicine should be permitted.
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Germline (oocyte, sperm, zygote, and embryo) gene
modification has been considered to be efficacious
against some genetic diseases due to its impact on the
entire body of the offspring. However, there has emerged
a global consensus that such gene modifications should
be forbidden owing to safety concerns [1-4], unprece-
dented informed consent [1,2], challenges to human dig-
nity [5], and the potential for permanent negative impact
on future generations, including its abuse for eugenics
or enhancement (the parental pursuit of specific traits
for non-medical reasons) [2,3,6-8]. Indeed, human germ-
line gene modification is largely forbidden by law or
guidelines even in countries that are permissive to hu-
man embryonic stem cell research [9].
Meanwhile, in the late 90′s, the infusion of oocyte-
cytoplasm, including mitochondria, was conducted to
enhance the viability of oocytes in the USA [10]. This
ooplasmic transfer needs an oocyte donor and is a
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unless otherwise stated.heteroplasmy in the resulting oocyte [11,12]. Although
ooplasmic transfer led to more than 30 childbirths, the
Food and Drug Administration (FDA) decided to regu-
late this procedure owing to potential health risk to pro-
geny [13]. More recently, mitochondrial replacement,
including pronuclear transfer between embryos [14] and
maternal spindle transfer between oocytes [15,16], has
been developed and is proposed as novel medicine in
order to prevent maternal transmission of serious mito-
chondrial diseases that result from aberrant mitochon-
drial DNA (mtDNA) in patient’s oocyte. Mitochondrial
replacement is also a form of germline gene modification
because this procedure involves altering the mtDNA
content of human oocytes or embryos. In addition, mito-
chondrial replacement as well as ooplasmic transfer re-
quire at the very least oocyte donation which could
potentially cause ovarian hyperstimulation syndrome in
female donors [9]. Currently, the US FDA weighs the
merits of the mitochondrial replacement [17]. Moreover,
the UK Department of Health (DH) considers lifting the
ban of mitochondrial replacement that is illegal in the
UK at present [18]. In response to the result of publicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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regulations to permit mitochondrial replacement [19].
Such possible regulatory changes, which occur in a few,
but major countries, may impact the international regu-
latory landscape that prohibits human germline gene
modification.
Recent advances in genetic engineering are also likely
to impact the international regulatory landscape.
Present-day genome editing technology, such as zinc fin-
ger nucleases (ZFNs), transcription activator-like effector
nucleases (TALENs), and clustered regularly interspaced
short palindromic repeat (CRISPR)/Cas system, have
achieved far more efficient genetic engineering in higher
organisms than the older techniques [20-23]. Of genome
editing technologies, the application of ZFNs has already
reached to a clinical stage in AIDS therapy that is based
on the administration of human chemokine receptor 5
(CCR5)-modified T cells [24]. ZFN-mediated homology-
directed repair has achieved correction of the mutations
associated with X-linked severe combined immune defi-
ciency (SCID) and haemostasis in somatic cells [25,26].
Moreover, gene corrections by ZFNs have been reported
regarding induced pluripotent stem cells derived somatic
cells biopsied from patients with sickle cell disease,
alpha1-antitrypsin deficiency, and Parkinson’s disease
[27-30]. With regard to CRISPR/Cas9, it was demon-
strated that those engineered nucleases can correct a
mutation in intestinal stem cells derived from patients
with cystic fibrosis [31]. Specific elimination of mutant
mitochondrial genomes in patient-derived cells was
attained by a new form of TALENs that can localize to
mitochondria and cleave different classes of pathogenic
mtDNA mutations [32].
Most notably, two reports emerged in 2014, demon-
strating that the microinjection of Cas9 or TALENs into
one-cell-stage embryos led to efficient generation of
targeted gene-modified non-human primates (NHPs)
[33,34]. In addition, the microinjection of Cas9 system
into mouse zygotes successfully corrected a 1 bp dele-
tion in a targeted gene and prevented the onset of cata-
racts in that mouse’s offspring [35]. Thereafter, some
experts, including a Nobel laureate, suggest increasing
feasibility of human germline gene modification medi-
ated by genome editing [36-38]. In the genome editing
of mammals, targeted gene modification is frequently
carried out by simply microinjecting of genome editing
system which consists of the nuclease mRNAs (or plas-
mids harboring the nuclease gene), single guide RNAs
(sgRNAs for Cas9), and a homology-containing donor
DNA template (if necessary) into animal embryos made
by in vitro fertilization (IVF) or intracytoplasmic sperm
injection (ICSI) [33-35,39-48]. Remarkably, this micro-
injection process resembles ICSI, one of assisted repro-
ductive technology (ART) to facilitate fertilization infertility clinics. Mammalian embryonic stem cells (ESCs),
including human ESCs, have also been more efficiently
modified by genome editing [35,42,43,49-53]. Thus,
rapid advances in genetic engineering render germline
gene modification more feasible in higher animals. Gen-
ome editing technology is more likely to develop into
medicine for preventing a genetic disease if corrective
genome editing is integrated into assisted reproductive
technology (ART), including IVF and ICSI. Importantly,
germline gene correction by genome editing does not re-
quire cell donation such as oocyte donation that is
needed for ooplasmic transfer and mitochondrial re-
placement. However, there are many issues that still
need to be addressed before genome editing-mediated
germline gene correction for preventive medicine could
occur. We herein investigated current status of genome
editing which modifies mammalian zygotes and embry-
onic stem cells as well as international regulations with
regard to human germline gene modification. As a
consequence, it was predicted that there would occur
regulatory issues surrounding genome editing-mediated
germline gene correction worldwide when the efficiency
of genome editing technology is further improved.
Moreover, we discuss forthcoming ethical and social is-
sues that corrective genome editing would raise in the
field of reproductive medicine.
Potential subjects for genome editing-mediated germline
gene correction
Genetic engineering can produce site-specific mutations
in cells or an organism. However, conventional genetic
engineering can be extremely laborious and require
time-consuming screens to identify a desired gene modi-
fication particularly in higher organisms. Genome edit-
ing technology is more efficient genetic engineering that
can directly modify a gene within a genome in various
organisms. This efficient gene modification is attained by a
microorganism-originated, engineered nuclease that causes
double-stranded breaks (DSBs) at a targeted sequence and
induces DNA repair through non-homologous end-joining
(NHEJ) or homology-directed repair (HDR) (Figure 1).
The NHEJ is a DSB repair pathway that ligates or joins
two broken ends together without a homologous tem-
plate for repair, thus leading to the introduction of small
insertions or deletions (indels) at the site of the DSB.
The HDR is a DNA template-dependent pathway for
DSB repair, using a homology-containing donor tem-
plate along with a site-specific genome editing nuclease,
enabling the insertion of single or multiple transgenes
(gene addition) in addition to single-nucleotide substi-
tutions in which an amino acid substitution of a protein
occurs (gene modification), or a mutation is completely
repaired in the resultant organism genome (gene cor-
rection). Remarkably, genome editing technologies do
Figure 1 Engineered nuclease-induced genome editing pathways. Double-stranded breaks (DSBs) are induced at a targeted sequence by a
microorganism-originated, engineered nuclease. Non-homologous end-joining (NHEJ) is a DSB repair pathway that ligates or joins two broken
ends together, resulting in the introduction of small insertions or deletions (indels) at the site of the DSB. Homology-directed repair (HDR) is a
DNA template-dependent pathway for DSB repair, using a homology-containing donor template along with a site-specific nuclease, enabling the
insertion of single or multiple transgenes (gene addition) in addition to single-nucleotide substitutions in which an amino acid substitution of a
protein occurs (gene modification), or a mutation is completely repaired in the resultant organism genome (gene correction).
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sites that result from the Cre/loxP recombination system
in transgenic mice, following the modifications. However,
there are still some technical issues in genome editing.
Identifying desired cells or animals which have an
intentional mutation among arising variants still require
careful screening, despite less laborious than conventional
methods. Moreover, genome editing technology may fail
to induce a biallelic modification in an animal, thereby
resulting in only an animal with a monoallelic modifica-
tion. The engineered nucleases could also cause off-target
mutations other than desired gene modification in a target
sequence [35,39-41,44,49-51]. Furthermore, the micro-
injection of the nuclease mRNAs into zygotes may induce
not only germline modifications but also mosaic modifica-
tions in which wild-type cells, including germline cells,
and genetically modified cells coexist in the resultant
animals [41,47]. Therefore, the entire process of genome
editing must be cautiously controlled by genetic analysis,
meticulous screening, and sufficient characterization of
resulting animals.
If corrective genome editing is integrated into ART,
represented by IVF and ICSI, the major medical implica-
tions of the germline gene correction are preventive
medicine rather than therapy, because this type of med-
ical procedure aims at not the treatment of existingpatients, but the prevention of transmission of a genetic
disease to offspring [54]. For this reason, potential sub-
jects would include those with congenital anomalies that
are caused by chromosomal, monogenic, multifactorial,
or environmental/teratogenic factors [55]. Among these,
a monogenic disease would be the initial candidate for
clinical application, since genome editing can efficiently
repair such a small mutation in the human germline.
However, medical use of genome editing for preventing
transmission of a monogenic disease should be limited
to cases where the medical benefits exceed the potential
health risks associated with the genetic intervention, im-
plying definite inheritance by the offspring. For instance,
an autosomal recessive disease in which both parents are
homozygous (e.g. cystic fibrosis [56], phenylketonuria
[57]) or an autosomal dominant disease where at least
one parent is homozygous (e.g. Huntington’s disease
[58], familial adenomatous polyposis [59]) is likely to be
considered. Genome editing-mediated germline gene
correction which could potentially cause off-target mu-
tations is not likely to be considered elsewhere for the
time being because preimplantation genetic diagnosis
(PGD) may circumvent an affected pregnancy by select-
ing IVF embryos with no suspected mutations [60].
Although clinical cases in which genome editing-
mediated germline gene correction is efficacious and
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genetic background, as well as a monogenic disease,
such cases will likely be found. If affected parents use a
medical procedure that prevents offspring from inheriting
their devastating disease, the public would sympathize
with them, similar to the case in mitochondrial replace-
ment [9]. One might assert that affected parents should
not use such a risky genetic intervention, and should in-
stead use donor gametes or donor embryos. However,
the parents should not be forced to use these reproduct-
ive options. Most parents wish to have their own
genetically-related healthy child. Therefore, the use ofFigure 2 Embryonic stem cell approach and zygote approach for genom
Zygotes with a mutation are treated with genome editing-mediated gene
After embryo screening by preimplantation genetic diagnosis, one or mor
are subjected to embryo transfer. NIPT can be used to confirm the genetic co
whether a fetus has genetic mosaic mutations. Long-term follow-up is require
germline to the entire body. CVS: chorionic villus sampling, ESCs: embryonic s
in vitro fertilization, NIPT: non-invasive prenatal genetic testing, NT: nuclear trasuch a medical procedure could represent an alternative
reproductive option.
Approaches for genome editing-mediated gene
correction
We considered two possible approaches for genome
editing-mediated germline gene correction to prevent
definite inheritance of a genetic disease (Figure 2). If one
attempts to repair a mutation directly in oocytes or em-
bryos by means of an older homologous recombination
technique, this attempt is likely to be a failure owing to
its low efficiency. Therefore, genome editing-mediatede editing-mediated gene correction to prevent a genetic disease.
correction via embryonic stem cell approach or zygote approach.
e embryos which have a corrected gene with no off-target mutations
ndition of the fetus. Subsequently, CVS or amniocentesis can confirm
d even after a successful birth owing to the contribution of the modified
tem cells, ET: embryo transfer, ICSI: intracytoplasmic sperm injection, IVF:
nsfer.
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ent’s embryo made by IVF or ICSI could represent an al-
ternative approach. Taking advantage of the self-renewal
of ESCs, in vitro expansion and cryopreservation of
ESCs enables repeated attempts to correct a mutation in
a specific gene by genome editing. According to reports
regarding genome editing of mammalian ESCs, the effi-
ciencies of indel and gene addition are 14 to 91% by
Cas9 and 0 to 83.49% by ZFNs or TALENs, respectively
(Table 1). Importantly, the efficiency, 83.49% was achieved
in a human ESC experiment for gene addition by ZFNs.
The efficiency of NHEJ-mediated indel is high even in the
simultaneous mutations of three loci (14%, 21%). In con-
trast, the efficiency of the HDR-mediated gene addition
may depend on the selection of a targeted gene. Of note,
both ZFNs and TALENs could not attain homozygous
gene addition in the OCT4 of human ESCs [50,51]. Com-
pared with these results regarding indel and gene addition,
the efficiency of targeted gene correction by ZFNs or Cas9
is low in human ESCs (Table 1). On a closer examination,
however, the efficiency of gene correction of integrated
GFP with ZFNs was 0.24%, a > 2400-fold increase as com-
pared with gene correction without ZFNs in Human ESCs
[52]. In mouse ESCs, the best result of gene correction,
44.4% was obtained in a case of a well-designed guide
RNA in Cas9 system (Table 1), although two occurrences
of off-target mutations were observed [35]. Off-targetTable 1 Genome editing of mammalian embryonic stem cells




Tet1, Tet2, Tet3 91% (Single locus), 45% (D
14% (Triple)
Mouse ESCs Tet1, Tet2, Tet3, Sry, Uty 56 ~ 77% (Single; Tet1,2,3
(Triple; Tet1,2,3)
HDR for Gene Addition
Human
ESCs
GFP into CCR5 5.3%
Human
ESCs
PGK-HygroR into, PIG-A 0.19 ~ 83.49%
Human
ESCs
GFP (or PURO) into, AAVS1, OCT4,
PITX




GFP (and/or PURO), into. AAVS1,
OCT4, PITX3
9 ~ 22% (AAVS1), 1 ~ 2%
0% (OCT4)
HDR for Gene Correction or Modification
Human
ESCs
Removal of Integrated GFP 0.24%
Human
ESCs
Introduction of HindIII cleavage
site into EMX1
0.4%
Mouse ESCs Crytg with 1 bp deletion in exon3 0 ~ 44.4%
ESCs; embryonic stem cells, NHEJ; non-homologous end-joining, HDR; homology-di
guide RNA, N.D.; not determined.
*Biallelic modification.mutations were also observed in the three reports regard-
ing gene addition in human ESCs [49-51]. In preclinical
research, meticulously designing and validating Zinc finger
domains in ZFNs, TALE subunits in TALENs, and
sgRNAs in CRISPER/Cas which are specific to a target site
of a gene is required in order to maximize the efficiency of
desired gene modification and minimize the possibility of
off-target mutations in genome editing-mediated gene
correction.
Such outcome suggests the attainability of genome
editing-mediated gene correction in some cases of human
ESCs if modified ESCs are carefully analysed regarding the
occurrence of off-target mutations. Subsequently, a karyo-
plast removed from a genetically corrected ESC can be
transferred to an enucleated oocyte retrieved from a fe-
male parent, and the resultant embryo can be cultured
and transferred to the female recipient. The step is also
considered to be potentially feasible in human because a
similar approach with somatic cells modified by ZFNs has
already been used for the generation of a biallelic knock-
out in pigs [61]. Additionally, human somatic cell nuclear
transfer (SCNT)-derived blastocysts have been recently
produced by at least three independent groups [62-64].
Remarkably, the approach does not imply cloning of a
living human if this is used only once for the birth of
one child. Nonetheless, the ESC approach has some dis-





ouble), N.D. Cas9 Plasmid/sgRNA [53]
), 21% No Cas9 Plasmid [43]
Yes ZFNs Lentivirus [49]
N.D. ZFNs Plasmid [52]
(OCT4, No (AAVS1, OCT4), Yes
(PITX3)
ZFNs Plasmid [50]
(PITX3), Yes (AAVS1, OCT4), N.
D. (PITX3)
TALENs Plasmid [51]






Yes Cas9 Plasmid [35]
rected repair, GFP; green fluorescent protein, PURO; puromycin, sgRNA; single
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or recombinant growth factors from non-human species
are used in human ES medium. However, this risk can
be circumvented if a xeno-free culture system is adopted.
Moreover, although electroporation or transfection re-
agents might cause cytotoxicity [52], preliminary re-
search would decrease such risks. Most importantly,
uncertainties may occur due to the complexity of this
approach. Human ESCs have a progressive tendency to
acquire genetic changes in the nucleus and/or mito-
chondria during prolonged culture [65-68]. Moreover,
not all ESC colonies in a dish are composed of the same
clones. Mutant clones might be mixed into a colony
during a subsequent NT procedure.
In contrast to the ESC approach, zygote approach is
best characterized by fewer steps (Figure 2). Genome
editing system is simply injected into the cytoplasm or
pronuclear of zygotes to correct a mutation in a gene.
After embryo screening, one or more embryos which
have a corrected gene with no off-target mutations are
then subjected to embryo transfer. Non-invasive prenatal
genetic testing, which uses maternal blood containing
cell-free fetal DNA [69], can be used to confirm the gen-
etic condition of the fetus. Subsequently, invasive genetic
testing, such as chorionic villus sampling or amniocen-
tesis, can confirm whether a fetus has genetic mosaic
mutations, although these diagnostics are associated
with a potential risk of miscarriage. Long-term follow-up
would be required even after a successful birth owing to
the contribution of the modified germline to the entire
body.
Microinjection of genome editing system into mam-
malian zygotes frequently results in efficient gene modi-
fication. According to recent reports, the efficiency of
indel in a single gene by TALENs or Cas9 ranges from
0.5% to 40.9% per injected zygotes (Table 2). Remark-
ably, the efficiency, 40.9% was attained in non-human
primate (NHP) embryos by injecting Cas9 system com-
posed of mRNAs and sgRNAs. In this experiment, a set
of twin female neonates with both modified Rag1 and
Ppar-γ were born. In addition, Ran et al. reported that
Cas9 nickase treatment can induce indels in Mecp2 at
80 to 100 percent of mouse blastocysts [42]. Regarding
gene modification in neonates, the efficiencies of indel
and gene addition are 0 to 41.7% by TALENs or Cas9,
and 1.7 and 3.0% by Cas9, respectively (Table 2). In the
targeted gene correction or modification, the efficiency
is 2.0 to 6.0% in mouse neonates (Table 2). However,
these gene correction or modification experiments re-
sulted in the occurrence of off-target mutations (Table 2).
The use of Cas9 nickase mutant resulted in less off-target
mutations than wild type Cas9, but could not solve the
off-target problem completely [44]. The Cas9-mediated
HDR by an exogenously provided oligonucleotide or theendogenous wild type allele was accompanied by rare but
significant off-target mutations in the mouse gene correc-
tion experiment [35]. Moreover, although no detectable
mutations were found in the predefined potential off-
target sites in the modified NHPs [33,34], in another NHP
experiment, a modified monkey which was treated with
TALENs appeared to be mosaic [47] (Table 2).
Zygote approach requires the PGD from the cleavage-
stage (on day 3 of development) to blastocyst stage (on
day 5 of development) to confirm no off-target muta-
tions and complete correction of a mutation prior to
embryo transfer. Although no mutations were detected
in the predefined potential off-target sites in the NHPs
in previous studies [33,34], careful prior investigation is
needed to assess whether PGD can definitely confirm
genetic conditions in modified embryos. The PGD en-
tails the opening of the zona pellucida and the removal
of embryonic cell(s) from an embryo [60]. It implies that
the embryo undergoes physical interventions twice,
namely, microinjection of the genome editing system,
and the biopsy for PGD. If ICSI is used to increase a
success rate of fertilization and avoid polyspermy, three
interventions are conducted. Such physical interventions
might affect the subsequent development of the embryos
in vitro or in vivo. Moreover, a PGD is also challenging
and needs preclinical optimization because accurate gen-
etic testing depends on biopsied embryonic cell(s). Since
a cleavage-stage embryo is composed of six to eight
cells, a single cell biopsy is widely used for PGD [60].
However, mosaicism which affects 15-80% of embryos
may impact the interpretation of PGD results [70-72].
Meanwhile, in the blastocyst stage, the embryo consists
of approximately 130 cells in the inner cell mass which
subsequently develops into the fetus and the surround-
ing trophectoderm. Recently, trophectoderm cells have
been biopsied from a blastocyst for PGD in order to
avoid damaging the embryo [60]. Although mosaicism
remains at the blastocyst stage [70-72], the result of a re-
cent randomized clinical trial supports that a single cell
biopsy at the cleavage-stage is more significantly dam-
aging to the embryo than biopsy at the blastocyst stage,
and resulted in poorer clinical outcomes [73]. Therefore,
sufficiently optimized, trophectoderm biopsy-based PGD
may be effective in the zygote approach.
Furthermore, the microinjection of genome editing
system into one-cell-stage embryos needs scrutiny at the
molecular level. The nuclear status transitions occur
during the one-cell-stage, encompassing the separated
oocyte and sperm pronuclei, pronuclear fusion, and
cleavage to the two-cell-stage. Currently, pronuclear in-
jection and cytoplasmic injection are adopted to intro-
duce genome editing system into mammalian zygotes
(Table 2). For this reason, the injection method and
timing of microinjection must be optimized since
Table 2 Genome editing of mammalian zygotes



















- No Cas9 mRNA/
sgRNA
A set of twin female monkeys





MECP2 - 9.5% (Rhesus), 3.7%
(Cynomolgus)
No TALENs Plasmid Three miscarried rhesus and





MECP2 - (2.0%) N.D. TALENs mRNA A modified male monkey




LDLR 3.8% - N.D. TALENs mRNA Cytoplasmic injection [46]
Porcine,
zygotes
RELA 0.5% - N.D. TALENs mRNA Cytoplasmic injection [46]
Rat,
zygotes










Tet1,Tet2,Tet3 - 14.3 ~ 18.8%
(Double; Tet1,2),
18.6% (Triple)



























Exo1 1.4 ~ 6.8% 0 ~ 10.3% N.D. TALENs mRNA Pronuclear injection [48]
Mouse,
zygotes





Fgf10 - 1.3 ~ 1.5% N.D. TALENs mRNA/
sgRNA
Cytoplasmic injection [45]
































Crytg with 1 bp
deletion in
exon3





















*Genetically modified embryos per injected zygote (%). **Genetically modified neonates (including fetus) per transferred embryo (%). †Genetically modified
blastocysts per blastocyst which underwent Cas9 treatment (%).
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tion may fail to prevent a genetic disease. In addition,
the cytotoxicity caused by the genome editing system in-
troduced in the form of a plasmid, mRNA, or protein,
with or without the short repair template DNA, should
be respectively investigated [21]. In doing so, the best
dose should also be considered to assure a completeDNA repair with less cytotoxicity. In recent two reports,
it was demonstrated that ZFN and TALEN proteins are
capable of crossing cell membranes and inducing en-
dogenous gene disruption [34,74]. This approach, des-
pite difficulty in the preparation of the protein, has some
advantages over DNA-based delivery methods. This de-
livery method can limit the time that cells are exposed
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tivity. Moreover, this method reduces the cell-type de-
pendency and toxicity of viral and nonviral gene delivery
systems.
Collectively, the zygote approach has advantages over
the ESC approach in terms of its simplicity, implying
that it may be more controllable protocol. Additionally,
the zygote approach is not associated with the potential
ethical issues of human cloning discussed in the ESC ap-
proach. If more efficient gene correction is attained by
improved genome editing, and if 13 to 15 oocytes, which
is optimum number of oocytes for a successful first IVF
cycle [75,76], can be retrieved from female patients, zyg-
ote approach is more likely to be feasible in a clinical
setting. One of the latest genome editing system, Cas9 is
increasingly used for zygote approach due to the ease of
preparation (Table 2). In contrast, Cas9 is considered to
cause higher off-target mutations than ZFNs and
TALENs [42]. However, Cas9 has been rapidly improved,
demonstrating that the combination of a Cas9 nickase
mutant and paired gRNAs, the truncation of gRNAs, or
the fusion of inactive Cas9 to Fok I nuclease can im-
prove the specificity of targeted gene modification
[42,77,78]. Although there might be difficulties in pre-
clinical optimization, rapid advances in genome editing
would make technical obstacles surmounted, and de-
velop germline gene correction into a medical procedure
in the immediate future.
International regulatory landscape
The preclinical research being performed to optimize
the microinjection of genome editing system into one-
cell-stage embryos requires human embryos for research
use. However, for ethical reasons, many countries or
states have strict regulations regarding the creation of
human embryos for research [79]. Yet, in some coun-
tries, surplus cryopreserved embryos which were origin-
ally created by IVF or ICSI and are no longer used for
reproduction are available, and researchers are permitted
to derive ESCs from the surplus embryos as long as they
have informed consent of the parents who underwent
fertility treatment, after approval of an institutional re-
view board (IRB) or equivalent bodies, and/or a national
review. Such surplus IVF embryos might facilitate opti-
mizing the microinjection procedure if the culture
period is within the 14th day of embryo development or
until the beginning of formation of primitive streak [79].
More importantly, as mentioned in the Background,
many countries ban human germline gene modification.
We recently surveyed fourteen countries which are per-
missive to human ESC research, with regard to whether
these countries permit human germline gene modifica-
tion [9]. The result showed that thirteen of these coun-
tries prohibit the gene modification, and in the USA,FDA regulates the clinical trial, whereas the NIH re-
stricts the application of germline gene modification. In
order to examine an international regulatory landscape,
we expanded our survey to 39 countries which included
the 14 countries. As a result, 29 countries were found to
ban germline gene modification. The remaining 10
countries include 9 countries which were ambiguous
about the legal status of the modification, and the USA
(Figure 3, see Additional file 1: Table S1).
Among the 29 countries, China, India, Ireland, and
Japan forbid it based on guidelines that are less enforce-
able than laws, and are subject to amendment (Additional
file 1: Table S1). The regulatory landscape suggests that
human germline gene modification is not totally prohib-
ited worldwide although there is room for further investi-
gation regarding the “ambiguous” countries. Again, the
USA currently does not ban, but has imposed a temporary
moratorium on the germline gene modification under the
FDA vigilance and the NIH guidelines (Additional file 1:
Table S1). When the safety of genome editing-mediated
germline gene correction is enhanced, the four countries
mentioned above and the USA might permit it. In addition,
Israel, which explicitly bans germline gene modification,
but has possible exemptions in the relevant law may permit
it upon the recommendation of an advisory committee [9].
This Israeli law is temporary legislation until May 23, 2016
(Additional file 1: Table S1). After that, the country might
permit human germline gene modification. In the UK, the
DH will consider the timing of the regulations to permit
mitochondrial replacement that is currently illegal mtDNA
alternation in the germline [19]. However, carefully taking
into consideration that there is no legal ban on research on
the human germline gene modification as long as the
Human Fertilisation and Embryology Authority (HFEA)
licenses such research in the UK, the legalization of
medical use of mitochondrial replacement is likely to
lead to legal permission for the modification of germline
nuclear genome that can be readily changed by genome
editing technology [80].
We recently argued that there are indistinct regula-
tory boundaries regarding genome editing technology
created in the regulations that govern genetically modi-
fied organisms (GMOs) [81]. One of the major issues
was how organisms modified using genome editing are
viewed in the process-based or product-based GMO
regulations. A similar debate may occur regarding the
medical use of genome editing. Remarkably, Belgium,
Bulgaria, Canada, Denmark, Sweden, and the Czech Re-
public ban germline gene modification on the grounds
that a modified gene may be inherited by offspring or
that the gene modification may impair human embryo
(Additional file 1: Table S1). However, it is unclear
whether genome editing-mediated germline gene cor-
rection is rendered illegal in those countries when
Figure 3 An international regulatory landscape regarding human germline gene modification. Thirty nine countries were surveyed and
categorized as “Ban based on legislation” (25, pink), “Ban based on guidelines” (4, faint pink), “Ambiguous” (9, gray), and “Restrictive” (1, light gray).
Non-colored countries were excluded in this survey. See also Additional file 1: Table S1.
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http://www.rbej.com/content/12/1/108genome editing can more efficiently correct a mutation
in the germline. One would assert that such an act is
legal, because the HDR-mediated germline gene correc-
tion results in a wild type status that can contribute
to normal embryonic development. In contrast, others
would dissent from this assertion, because genome
editing-mediated germline gene modification can be
regarded as a grave intervention in human life. Many
arguments are more likely to occur with respect to the
lawfulness of genome editing-mediated germline gene
modification for medical purposes.
Ethical and social issues
In an IRB review of an application for the HDR-
mediated germline gene correction, the unavailability of
informed consent from an unborn child may constitute
grounds for ethical refusal. Yet, informed consent to the
germline gene correction by parents may be justified if
its safety is equivalent to that of ART, such as ICSI,
which are currently conducted with informed consent
provided by prospective parent(s) [9]. Still, there are dif-
ficult questions to be addressed. The condition of bothparents would be questioned from various viewpoints.
For instance, a board member might ask whether a fe-
male parent can safely undergo oocyte retrieval which
encompasses the need of medication, a hormone injec-
tion, and transvaginal retrieval with a potential risk of
ovarian hyperstimulation syndrome [82], in addition to
pregnancy and delivery. Moreover, another member
might ask whether the affected parents can foster the
healthy child that was born of the procedure.
From a societal viewpoint, different issues would
emerge when genome editing-mediated germline gene
correction is practiced for preventive medicine. A regu-
latory agency would require that practitioners should
fulfil long-term monitoring and healthcare of children
born using the procedure because it could be associated
with a potential risk of health impairment. However, it is
difficult to determine how long such children must be
monitored. Does the monitoring last during their whole
lives or across several generations of the offspring? With
regard to the mitochondrial replacement, the UK HFEA
declared that it would be necessary to monitor the
resulting children during their lifetime and ensure the
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http://www.rbej.com/content/12/1/108traceability of gametes and embryos [83]. However, it is
unlikely to be possible to perform such monitoring in all
relevant countries. Moreover, it is also difficult to decide
whether a country should aid all patients with thousands
of genetic diseases, or how to select the subjects for the
preventive medicine. If childbirth with a genetic disease
no longer occurs in a country due to the extensive practice
of the preventive medicine, it might impact the rights of
the disabled with the genetic disease, intentionally or un-
intentionally assuming a posture against the existing pa-
tients who deserve respect, dignity, and support. Social
cost of monitoring and healthcare would increase, as the
practice of the preventive medicine grows. There is an-
other social issue associated with healthcare costs. ART
is generally expensive and creates disparities in access
to this infertility services even in a country or a state
with insurance coverage [84,85]. The access to this pre-
ventive medicine would be completely confined to the
wealthier segment. Thus, there are many ethical and
social issues that should be addressed prior to the initi-
ation of genome editing-mediated germline gene correc-
tion for preventive medicine.
Conclusions
Genome editing-mediated germline gene correction for
preventive medicine appears to be an unprecedented
event in human history, since humans can correct a gen-
etic mutation in the embryo using this biotechnology
and potentially eradicate a congenital anomaly. We pre-
dict that corrective genome editing should reach a safe
level that permits clinical applications in the immediate
future. Each country will need to consider whether cor-
rective genome editing in the human germline should be
permitted with respect to socioethical implications as
well as safety and efficacy. Furthermore, if a country
positively considers the preventive medicine, the country
would be required to express preventive measures
against abuses of germline genome editing, and a global
consensus will need to be formed, because thinking
about germline gene modification involves ethical, social,
and evolutionary considerations for all of humankind.
Additional file
Additional file 1: Table S1. Policies on Human Germline Gene
Modification for Reproduction Excluding Reproductive Cloning.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MA and TI examined current development of genome editing in mammals
and considered the protocol for germline genome editing. TI surveyed
regulations regarding germline gene modification. TI conceived the study,
and MA participated in its design and helped to draft the manuscript. Both
authors read and approved the final manuscript.Acknowledgements
We thank Kumie Nojima (NIRS) for instructive comments prior to the
regulations survey. This work was supported by JSPS KAKENHI Grant Number
26460586 (TI). Our survey contains interpretation. We recommend
researchers to consult health authorities in their country.
Received: 15 August 2014 Accepted: 24 September 2014
Published: 24 November 2014
References
1. Billings PR, Hubbard R, Newman SA: Human germline gene modification:
a dissent. Lancet 1999, 353(9167):1873–1875.
2. Frankel MS, Chapman AR: Human Inheritable Genetic Modifications.
Assessing Scientific, Ethical, Religious and Policy Issues. In American
Association for the Advancement of Sciences. 2000. Search the article by
entering the article title at http://shr.aaas.org/projects/human_enhance/
reports/germline.pdf.
3. Davis BD: Germ-line therapy: evolutionary and moral considerations.
Hum Gene Ther 1992, 3(4):361–363.
4. Neel JV: Germ-line gene therapy: another view. Hum Gene Ther 1993,
4(2):127–128.
5. Glover J: What Sort of People Should There Be?. London: Penguin Books;
1984:45–47.
6. Lewis CS: The Abolition of Man. New York: Macmillan; 1965:69–71.
7. Ramsey P: Fabricated Man: The Ethics of Genetic Control. New Haven: Yale
University Press; 1970.
8. Sandel M: The case against perfection. Atl Mon 2004, 293:51–62.
9. Ishii T: Potential impact of human mitochondrial replacement on global
policy regarding germline gene modification. Reprod Biomed Online 2014,
29(2):150–155.
10. Cohen J, Scott R, Schimmel T, Levron J, Willadsen S: Birth of infant after
transfer of anucleate donor oocyte cytoplasm into recipient eggs. Lancet
1997, 350(9072):186–187.
11. Brenner CA, Barritt JA, Willadsen S, Cohen J: Mitochondrial DNA
heteroplasmy after human ooplasmic transplantation. Fertil Steril 2000,
74(3):573–578.
12. Barritt JA, Brenner CA, Malter HE, Cohen J: Mitochondria in human
offspring derived from ooplasmic transplantation. Hum Reprod 2001,
16(3):513–516.
13. FDA: Biological Response Modifiers Advisory Committee. Ooplasm transfer
as method to treat female infertility. May 9, 2002. http://www.fda.gov/ohrms/
dockets/ac/cber02.htm#Biological%20Response%20Modifiers.
14. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM,
Murdoch AP, Chinnery PF, Taylor RW, Lightowlers RN, Herbert M, Turnbull
DM: Pronuclear transfer in human embryos to prevent transmission of
mitochondrial DNA disease. Nature 2010, 465(7294):82–85.
15. Paull D, Emmanuele V, Weiss KA, Treff N, Stewart L, Hua H, Zimmer M,
Kahler DJ, Goland RS, Noggle SA, Prosser R, Hirano M, Sauer MV, Egli D:
Nuclear genome transfer in human oocytes eliminates mitochondrial
DNA variants. Nature 2013, 493(7434):632–637.
16. Tachibana M, Amato P, Sparman M, Woodward J, Sanchis DM, Ma H,
Gutierrez NM, Tippner-Hedges R, Kang E, Lee HS, Ramsey C, Masterson K,
Battaglia D, Lee D, Wu D, Jensen J, Patton P, Gokhale S, Stouffer R, Mitalipov
S: Towards germline gene therapy of inherited mitochondrial diseases.
Nature 2013, 493(7434):627–631.




18. DH: Mitochondrial Donation. In A Consultation Draft Regulations to Permit
the Use of New Treatment Techniques to Prevent the Transmission of a Serious
Mitochondrial Disease from Mother to Child. 2014. https://www.gov.uk/
government/consultations/serious-mitochondrial-disease-new-techniques-
to-prevent-transmission.
19. DH: Mitochondrial donation plans progress following consultation. 2014.
https://www.gov.uk/government/news/mitochondrial-donation-plans-
progress-following-consultation.
20. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD: Genome editing
with engineered zinc finger nucleases. Nat Rev Genet 2010, 11(9):636–646.
21. Gaj T, Gersbach CA, Barbas CF 3rd: ZFN, TALEN, and CRISPR/Cas-based
methods for genome engineering. Trends Biotechnol 2013, 31(7):397–405.
Araki and Ishii Reproductive Biology and Endocrinology 2014, 12:108 Page 11 of 12
http://www.rbej.com/content/12/1/10822. Joung JK, Sander JD: TALENs: a widely applicable technology for targeted
genome editing. Nat Rev Mol Cell Biol 2013, 14(1):49–55.
23. Sander JD, Joung JK: CRISPR-Cas systems for editing, regulating and
targeting genomes. Nat Biotechnol 2014, 32(4):347–355.
24. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT,
Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman
RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH: Gene editing
of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J
Med 2014, 370(10):901–910.
25. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson
AC, Porteus MH, Gregory PD, Holmes MC: Highly efficient endogenous
human gene correction using designed zinc-finger nucleases. Nature
2005, 435(7042):646–651.
26. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, Malani N, Anguela
XM, Sharma R, Ivanciu L, Murphy SL, Finn JD, Khazi FR, Zhou S, Paschon DE,
Rebar EJ, Bushman FD, Gregory PD, Holmes MC, High KA: In vivo genome
editing restores haemostasis in a mouse model of haemophilia. Nature
2011, 475(7355):217–221.
27. Zou J, Mali P, Huang X, Dowey SN, Cheng L: Site-specific gene correction
of a point mutation in human iPS cells derived from an adult patient
with sickle cell disease. Blood 2011, 118(17):4599–4608.
28. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT,
Goodwin MJ, Hawkins JS, Ramirez CL, Batista LF, Artandi SE, Wernig M,
Joung JK: In situ genetic correction of the sickle cell anemia mutation in
human induced pluripotent stem cells using engineered zinc finger
nucleases. Stem Cells 2011, 29(11):1717–1726.
29. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, Miranda
E, Ordonez A, Hannan NR, Rouhani FJ, Darche S, Alexander G, Marciniak SJ,
Fusaki N, Hasegawa M, Holmes MC, Di Santo JP, Lomas DA, Bradley A, Vallier
L: Targeted gene correction of alpha1-antitrypsin deficiency in induced
pluripotent stem cells. Nature 2011, 478(7369):391–394.
30. Soldner F, Laganiere J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R,
Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu
BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R:
Generation of isogenic pluripotent stem cells differing exclusively at two
early onset Parkinson point mutations. Cell 2011, 146(2):318–331.
31. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N,
Boymans S, Cuppen E, van der Ent CK, Nieuwenhuis EE, Beekman JM,
Clevers H: Functional repair of CFTR by CRISPR/Cas9 in intestinal stem
cell organoids of cystic fibrosis patients. Cell Stem Cell 2013, 13(6):653–658.
32. Bacman SR, Williams SL, Pinto M, Peralta S, Moraes CT: Specific elimination
of mutant mitochondrial genomes in patient-derived cells by mitoTA-
LENs. Nat Med 2013, 19(9):1111–1113.
33. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X, Si W, Li W,
Xiang AP, Zhou J, Guo X, Bi Y, Si C, Hu B, Dong G, Wang H, Zhou Z, Li T,
Tan T, Pu X, Wang F, Ji S, Zhou Q, Huang X, Ji W, Sha J: Generation of
gene-modified cynomolgus monkey via Cas9/RNA-mediated gene
targeting in one-cell embryos. Cell 2014, 156(4):836–843.
34. Liu H, Chen Y, Niu Y, Zhang K, Kang Y, Ge W, Liu X, Zhao E, Wang C, Lin S,
Jing B, Si C, Lin Q, Chen X, Lin H, Pu X, Wang Y, Qin B, Wang F, Wang H, Si
W, Zhou J, Tan T, Li T, Ji S, Xue Z, Luo Y, Cheng L, Zhou Q, Li S: TALEN-
mediated gene mutagenesis in rhesus and cynomolgus monkeys. Cell
Stem Cell 2014, 14(3):323–328.
35. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, Yan Z, Li D, Li J: Correction
of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013,
13(6):659–662.
36. Lokody I: Genetic therapies: Correcting genetic defects with CRISPRCas9.
Nat Rev Genet 2013, 15:63–63.
37. Pollack A: A Powerful New Way to Edit DNA. In The New York Times. 2014.
38. Cathomen T, Ehl S: Translating the genomic revolution - targeted
genome editing in primates. N Engl J Med 2014, 370(24):2342–2345.
39. Tesson L, Usal C, Menoret S, Leung E, Niles BJ, Remy S, Santiago Y, Vincent
AI, Meng X, Zhang L, Gregory PD, Anegon I, Cost GJ: Knockout rats
generated by embryo microinjection of TALENs. Nat Biotechnol 2011,
29(8):695–696.
40. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R: One-step
generation of mice carrying reporter and conditional alleles by CRISPR/
Cas-mediated genome engineering. Cell 2013, 154(6):1370–1379.
41. Li W, Teng F, Li T, Zhou Q: Simultaneous generation and germline
transmission of multiple gene mutations in rat using CRISPR-Cas
systems. Nat Biotechnol 2013, 31(8):684–686.42. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA,
Inoue A, Matoba S, Zhang Y, Zhang F: Double nicking by RNA-guided
CRISPR Cas9 for enhanced genome editing specificity. Cell 2013,
154(6):1380–1389.
43. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R:
One-step generation of mice carrying mutations in multiple genes by
CRISPR/Cas-mediated genome engineering. Cell 2013, 153(4):910–918.
44. Li F, Cowley DO, Banner D, Holle E, Zhang L, Su L: Efficient genetic
manipulation of the NOD-Rag1−/−IL2RgammaC-null mouse by combining
in vitro fertilization and CRISPR/Cas9 technology. Sci Rep 2014, 4:5290.
45. Yasue A, Mitsui SN, Watanabe T, Sakuma T, Oyadomari S, Yamamoto T,
Noji S, Mito T, Tanaka E: Highly efficient targeted mutagenesis in one-cell
mouse embryos mediated by the TALEN and CRISPR/Cas systems.
Sci Rep 2014, 4:5705.
46. Carlson DF, Tan W, Lillico SG, Stverakova D, Proudfoot C, Christian M, Voytas
DF, Long CR, Whitelaw CB, Fahrenkrug SC: Efficient TALEN-mediated gene
knockout in livestock. Proc Natl Acad Sci U S A 2012, 109(43):17382–17387.
47. Liu Z, Zhou X, Zhu Y, Chen ZF, Yu B, Wang Y, Zhang CC, Nie YH, Sang X, Cai
YJ, Zhang YF, Zhang C, Zhou WH, Sun Q, Qiu Z: Generation of a monkey
with MECP2 mutations by TALEN-based gene targeting. Neurosci Bull
2014, 30(3):381–386.
48. Mashimo T, Kaneko T, Sakuma T, Kobayashi J, Kunihiro Y, Voigt B,
Yamamoto T, Serikawa T: Efficient gene targeting by TAL effector
nucleases coinjected with exonucleases in zygotes. Sci Rep 2013, 3:1253.
49. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando
D, Urnov FD, Galli C, Gregory PD, Holmes MC, Naldini L: Gene editing in
human stem cells using zinc finger nucleases and integrase-defective
lentiviral vector delivery. Nat Biotechnol 2007, 25(11):1298–1306.
50. Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC,
Katibah GE, Amora R, Boydston EA, Zeitler B, Meng X, Miller JC, Zhang L,
Rebar EJ, Gregory PD, Urnov FD, Jaenisch R: Efficient targeting of
expressed and silent genes in human ESCs and iPSCs using zinc-finger
nucleases. Nat Biotechnol 2009, 27(9):851–857.
51. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang
L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng X, Hinkley SJ, Rebar EJ,
Gregory PD, Urnov FD, Jaenisch R: Genetic engineering of human
pluripotent cells using TALE nucleases. Nat Biotechnol 2011, 29(8):731–734.
52. Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK,
Chen G, Ye Z, Park IH, Daley GQ, Porteus MH, Joung JK, Cheng L: Gene
targeting of a disease-related gene in human induced pluripotent stem
and embryonic stem cells. Cell Stem Cell 2009, 5(1):97–110.
53. Li W, Li X, Li T, Jiang MG, Wan H, Luo GZ, Feng C, Cui X, Teng F, Yuan Y,
Zhou Q, Gu Q, Shuai L, Sha J, Xiao Y, Wang L, Liu Z, Wang XJ, Zhao XY,
Zhou Q: Genetic modification and screening in rat using haploid
embryonic stem cells. Cell Stem Cell 2014, 14(3):404–414.
54. Glass B: Science: endless horizons or golden age? Science 1971,
171(3966):23–29.
55. WHO: Congenital anomalies. Fact sheet No 370. 2014. http://www.who.
int/mediacentre/factsheets/fs370/en/.
56. Neocleous V, Yiallouros PK, Tanteles GA, Costi C, Moutafi M: Apparent
Homozygosity of p.Phe508del in CFTR due to a Large Gene Deletion of
Exons 4–11. Case Rep Genet 2014, 2014:613863.
57. Groselj U, Tansek MZ, Kovac J, Hovnik T, Podkrajsek KT, Battelino T: Five
novel mutations and two large deletions in a population analysis of the
phenylalanine hydroxylase gene. Mol Genet Metab 2012, 106(2):142–148.
58. Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC,
Almqvist EW, Turner D, Bachoud-Levi AC, Simpson SA, Delatycki M,
Maglione V, Hayden MR, Donato SD: Homozygosity for CAG mutation in
Huntington disease is associated with a more severe clinical course. Brain
2003, 126(Pt 4):946–955.
59. Cruz-Correa M, Diaz-Algorri Y, Mendez V, Vazquez PJ, Lozada ME, Freyre K,
Lathroum L, Gonzalez-Pons M, Hernandez-Marrero J, Giardiello F, Rodriguez-
Quilichini S: Clinical characterization and mutation spectrum in Hispanic
families with adenomatous polyposis syndromes. Familial Cancer 2013,
12(3):555–562.
60. Stern HJ: Preimplantation Genetic Diagnosis: Prenatal Testing for
Embryos Finally Achieving Its Potential. J Clin Med 2014, 3(1):280–309.
61. Hauschild J, Petersen B, Santiago Y, Queisser AL, Carnwath JW, Lucas-Hahn
A, Zhang L, Meng X, Gregory PD, Schwinzer R, Cost GJ, Niemann H: Efficient
generation of a biallelic knockout in pigs using zinc-finger nucleases.
Proc Natl Acad Sci U S A 2011, 108(29):12013–12017.
Araki and Ishii Reproductive Biology and Endocrinology 2014, 12:108 Page 12 of 12
http://www.rbej.com/content/12/1/10862. Tachibana M, Amato P, Sparman M, Gutierrez NM, Tippner-Hedges R, Ma H,
Kang E, Fulati A, Lee HS, Sritanaudomchai H, Masterson K, Larson J, Eaton D,
Sadler-Fredd K, Battaglia D, Lee D, Wu D, Jensen J, Patton P, Gokhale S,
Stouffer RL, Wolf D, Mitalipov S: Human embryonic stem cells derived by
somatic cell nuclear transfer. Cell 2013, 153(6):1228–1238.
63. Chung YG, Eum JH, Lee JE, Shim SH, Sepilian V, Hong SW, Lee Y, Treff NR,
Choi YH, Kimbrel EA, Dittman RE, Lanza R, Lee DR: Human somatic cell
nuclear transfer using adult cells. Cell Stem Cell 2014, 14(6):777–780.
64. Yamada M, Johannesson B, Sagi I, Burnett LC, Kort DH, Prosser RW, Paull D,
Nestor MW, Freeby M, Greenberg E, Goland RS, Leibel RL, Solomon SL,
Benvenisty N, Sauer MV, Egli D: Human oocytes reprogram adult somatic
nuclei of a type 1 diabetic to diploid pluripotent stem cells. Nature 2014,
510(7506):533–536.
65. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV,
Lee S, Barrero MJ, Ku S, Martynova M, Semechkin R, Galat V, Gottesfeld J,
Izpisua Belmonte JC, Murry C, Keirstead HS, Park HS, Schmidt U, Laslett AL,
Muller FJ, Nievergelt CM, Shamir R, Loring JF: Dynamic changes in the
copy number of pluripotency and cell proliferation genes in human
ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell
2011, 8(1):106–118.
66. Taapken SM, Nisler BS, Newton MA, Sampsell-Barron TL, Leonhard KA, McIntire
EM, Montgomery KD: Karotypic abnormalities in human induced pluripotent
stem cells and embryonic stem cells. Nat Biotechnol 2011, 29(4):313–314.
67. Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H,
Baker J, Baker D, Munoz MB, Beil S, Benvenisty N, Ben-Yosef D, Biancotti JC,
Bosman A, Brena RM, Brison D, Caisander G, Camarasa MV, Chen J, Chiao E,
Choi YM, Choo AB, Collins D, Colman A, Crook JM, Daley GQ, Dalton A, De
Sousa PA, Denning C, Downie J, et al: Screening ethnically diverse human
embryonic stem cells identifies a chromosome 20 minimal amplicon
conferring growth advantage. Nat Biotechnol 2011, 29(12):1132–1144.
68. Van Haute L, Spits C, Geens M, Seneca S, Sermon K: Human embryonic
stem cells commonly display large mitochondrial DNA deletions. Nat
Biotechnol 2013, 31(1):20–23.
69. Benn P: Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal
Plasma: Recent Developments and Future Prospects. J Clin Med 2014,
3(1):537–565.
70. Bielanska M, Tan SL, Ao A: Chromosomal mosaicism throughout human
preimplantation development in vitro: incidence, type, and relevance to
embryo outcome. Hum Reprod 2002, 17(2):413–419.
71. Bielanska M, Tan SL, Ao A: High rate of mixoploidy among human
blastocysts cultured in vitro. Fertil Steril 2002, 78(6):1248–1253.
72. Van Echten-Arends J, Mastenbroek S, Sikkema-Raddatz B, Korevaar JC, Heineman
MJ, van der Veen F, Repping S: Chromosomal mosaicism in human
preimplantation embryos: a systematic review. Hum Reprod Update
2011, 17(5):620–627.
73. Scott RT Jr, Upham KM, Forman EJ, Zhao T, Treff NR: Cleavage-stage biopsy
significantly impairs human embryonic implantation potential while
blastocyst biopsy does not: a randomized and paired clinical trial. Fertil
Steril 2013, 100(3):624–630.
74. Gaj T, Guo J, Kato Y, Sirk SJ, Barbas CF 3rd: Targeted gene knockout by
direct delivery of zinc-finger nuclease proteins. Nat Methods 2012,
9(8):805–807.
75. van der Gaast MH, Eijkemans MJ, van der Net JB, De Boer EJ, Burger CW,
Van Leeuwen FE, Fauser BC, Macklon NS: Optimum number of oocytes for
a successful first IVF treatment cycle. Reprod Biomed Online 2006, 13
(4):476–480.
76. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J,
Coomarasamy A: Association between the number of eggs and live birth
in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod
2011, 26(7):1768–1774.
77. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK: Improving CRISPR-Cas
nuclease specificity using truncated guide RNAs. Nat Biotechnol 2014,
32(3):279–284.
78. Guilinger JP, Thompson DB, Liu DR: Fusion of catalytically inactive Cas9 to
FokI nuclease improves the specificity of genome modification. Nat
Biotechnol 2014, 32(6):577–582.
79. Ishii T, Pera RA, Greely HT: Ethical and legal issues arising in research on
inducing human germ cells from pluripotent stem cells. Cell Stem Cell
2013, 13(2):145–148.
80. Wong CC, Johnson MH: Therapy for mitochondrial genetic disease: are we
at the thin end of the wedge? Reprod Biomed Online 2014, 29(2):147–149.81. Araki M, Nojima K, Ishii T: Caution required for handling genome editing
technology. Trends Biotechnol 2014, 32(5):234–237.
82. Orvieto R: Ovarian hyperstimulation syndrome- an optimal solution for
an unresolved enigma. J Ovarian Res 2013, 6(1):77.
83. HFEA: HFEA Statement Regarding the Klaus Reinhardt et al. Science
Paper ‘Mitochondrial Replacement, Evolution, and the Clinic’. 2013.
http://www.hfea.gov.uk/8178.html.
84. Jain T, Hornstein MD: Disparities in access to infertility services in a state
with mandated insurance coverage. Fertil Steril 2005, 84(1):221–223.
85. Nachtigall RD: International disparities in access to infertility services.
Fertil Steril 2006, 85(4):871–875.
doi:10.1186/1477-7827-12-108
Cite this article as: Araki and Ishii: International regulatory landscape and
integration of corrective genome editing into in vitro fertilization.
Reproductive Biology and Endocrinology 2014 12:108.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
